Exendin-4
| Category | Compounds |
|---|---|
| Also known as | Exenatide (synthetic form), Heloderma-derived GLP-1 Agonist |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | glp-1-agonistincretinmetabolicdiabetesresearch |
Overview
Exendin-4 is a naturally occurring peptide first isolated from the salivary secretions of the Gila monster (Heloderma suspectum). Despite its reptilian origin, it shares about 50% sequence identity with mammalian glucagon-like peptide-1 (GLP-1) and acts as a potent agonist at the GLP-1 receptor, while being resistant to degradation by dipeptidyl peptidase-4 (DPP-4). This combination of activity and stability made exendin-4 the basis for the first clinically approved GLP-1 receptor agonist, exenatide.
Exendin-4 research catalyzed the broader incretin-based therapy category that now includes peptides such as Liraglutide, Semaglutide, Lixisenatide, Dulaglutide, and dual agonists like Tirzepatide. As a research peptide, exendin-4 is often used in preclinical work where synthetic Exenatide would serve the same pharmacological role.
Because native GLP-1 has a half-life of only a few minutes due to rapid DPP-4 cleavage, exendin-4's natural DPP-4 resistance (conferred largely by its second residue, glycine) was a pivotal structural observation that guided subsequent drug design.
Structure / Chemistry
Exendin-4 is a 39-amino-acid peptide with an N-terminal histidine followed by a glycine at position 2 — the latter being key to DPP-4 resistance. It shares core receptor-binding residues with GLP-1 but includes a C-terminal "Trp-cage" extension that enhances receptor affinity.
Mechanism of Action
Exendin-4 binds the GLP-1 receptor with high affinity, triggering Gαs-mediated cAMP signaling in pancreatic β-cells. Downstream effects include glucose-dependent insulin secretion, suppression of glucagon, slowed gastric emptying, and central anorexigenic signaling. Glucose dependence of insulin release is a defining feature that limits hypoglycemia risk compared with sulfonylureas.
Research Summary
| Area | Finding | Reference |
|---|---|---|
| Discovery | Isolation from Gila monster venom | Eng et al., J Biol Chem 1992 |
| Diabetes | Efficacy as exenatide in type 2 diabetes | DeFronzo et al., Diabetes Care 2005 |
| Mechanism | GLP-1R agonism and insulin secretion | Göke et al., J Biol Chem 1993 |
| Neuroscience | Neuroprotective effects in Parkinson's models | Li et al., PNAS 2009 |
| PK | DPP-4 resistance and extended half-life | Greig et al., Diabetologia 1999 |
Pharmacokinetics
Exendin-4 has a plasma half-life of approximately 2-4 hours, dramatically longer than native GLP-1's 1-2 minutes. Its renal clearance is the primary elimination pathway. Clinical formulations (exenatide immediate-release and long-acting release) achieve different pharmacokinetic profiles using the same molecule. Specific doses are trial and clinical parameters.
Common Discussion Topics
- Historical significance as the first DPP-4-resistant GLP-1 agonist.
- Neuroscience research in Parkinson's disease models.
- Relationship to the marketed drug Exenatide.
- Immunogenicity considerations as a reptilian-origin peptide.
- Position within the broader incretin drug category.
Related Compounds
Sourcing research-grade compounds
Obtaining high-purity, research-grade Exendin-4 requires verified and trusted suppliers with third-party COA testing and transparent sourcing practices.
White Market Peptides — Verified Supplier →Join the discussion
See how the community is discussing Exendin-4. Share your experience, ask questions, and explore protocols on PepAtlas.
Related entries
- Exenatide— The first GLP-1 receptor agonist approved for type 2 diabetes, derived from exendin-4 found in Gila monster venom. Marketed as Byetta (twice-daily) and Bydureon (once-weekly extended-release).
- Liraglutide— A once-daily GLP-1 receptor agonist acylated with a C16 fatty acid for albumin binding, approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda).
- Lixisenatide—
- Semaglutide— A long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), with emerging cardiovascular, renal, and neurological research applications.
- Tirzepatide— A first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), demonstrating weight loss exceeding 20% in clinical trials.